期刊文献+

Molecular markers contribute to the clinical diagnosis for pancreatic cystic neoplasms

原文传递
导出
摘要 A pancreatic cystic neoplasm(PCN)is a rare pancreatic disease.Malignant PCNs are usually identified incidentally while evaluating other lesions.However,PCNs are being identified more frequently owing to the increased use of abdominal imaging.Malignant PCNs have complicated and diverse biological behaviors,including various malignant risk factors,diverse molecular features,natural history,and complex pathological classifications.Although many diagnostic methods,such as cross-sectional imaging and endoscopic evaluation,have been developed,malignant PCNs are still difficult to differentiate from benign tumors.On searching for related articles in the recent decade,we found that some molecular biomarkers such as carcinoembryonic antigen could be useful for discriminating between malignant tumors and benign tumors.However,cytopathologic evaluation is the most useful method for differentiating between benign and malignant lesions.Although cytopathologic evaluation has a specificity of 100%for identifying malignancies,its accuracy is often hampered by the low cellularity of PCN cells in the cystic fluid.Herein,we review the progress in the use of cellular and molecular markers for the accurate identification of PCNs.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2020年第7期847-852,共6页 中华医学杂志(英文版)
  • 相关文献

参考文献2

二级参考文献2

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部